H.C. Wainwright analyst Edward White maintained a Buy rating on Dynavax (NASDAQ:DVAX) Technologies Corp. on Wednesday, setting a price target of $23, which is approximately 44.02% above the present share price of $15.97.
White expects Dynavax Technologies Corp. to post earnings per share (EPS) of -$0.24 for the fourth quarter of 2021.
The current consensus among 4 TipRanks analysts is for a Strong Buy rating of shares in Dynavax, with an average price target of $26.
The analysts price targets range from a high of $30 to a low of $23.
In its latest earnings report, released on 09/30/2021, the company reported a quarterly revenue of $108.27 million and a net profit of $15.07 million. The company's market cap is $1.92 billion.
According to TipRanks.com, H.C. Wainwright analyst Edward White is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 23.7% and a 43.87% success rate.
Dynavax Technologies Corp. is a biopharmaceutical company, which engages in the development and discovery of novel vaccines and immuno-oncology therapeutics. It focuses on leveraging the body's innate and adaptive immune responses through toll-like receptor stimulation. It offers products for vaccines, cancer immunotherapy, and immune-mediated diseases. The company was founded by Lawrence M. Lichtenstein, Dennis A. Carson, and Eyal Raz on August 29, 1996 and is headquartered in Berkeley, CA.